Contact Information for Healthcare Professionals

Please contact the patient's haematologist (details overleaf) for more information.

Please consult the Summary of Product Characteristics for Lunsumio available at: www.medicines.org.uk; or contact Roche Medical Information (tel: 0800 328 1629, email: medinfo.uk@roche.com).

▼This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get.

Important Information for Patients

If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet.

Please report suspected side effects to the MHRA through the Yellow Card scheme, via the Yellow Card website www.mhra.gov.uk/yellowcard,or the free Yellow Card app available in the Apple App Store or Google Play Store. Alternatively you can call 0800 731 6789 for free, Monday to Friday between 9am and 5pm.

You should also report side effects to Roche Products Ltd by emailing the Roche Drug Safety Centre at welwyn.uk_dsc@roche.com or calling +44 (0)1707 367554.
By reporting side effects you can help provide more information on the safety of this medicine.

Date of Lunsumio initiation:

Name of haematologist:

Contact Number:

After-hours contact number:

My name:

My contact number:

Emergency contact:

Emergency contact number:

Roche

Important Safety Information for Patients receiving Lunsumio®▼ (mosunetuzumab)

Lunsumio as monotherapy is indicated for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) who have received at least two prior systemic therapies.

Patient Card

This educational material is provided by Roche Products Limited and is mandatory as a condition of the Marketing Authorisation in order to further minimise important selected risks.

M-GB-00020099 Date of preparation: November 2024

Version 2.0.1 MHRA Approval Date: December 2024

Please carry this card with you at all times while you are receiving Lunsumio.

Show this card to ALL Healthcare Professionals (including doctors, nurses, pharmacists) involved in your treatment and at any visits to the hospital.

Important Information for the Patient/Caregiver

Contact your Doctor or get emergency help right away if you have any of these symptoms. Do not attempt to diagnose and treat these symptoms yourself.

Cytokine Release Syndrome (CRS) symptoms to monitor for:

- Fever (38°C or higher)
- Fast or irregular heartbeat
- Chills or shaking chills
- Confusion
- Severe fatigue or weakness
- Difficulty breathing
- Dizziness or light-headedness
- Fainting or blurred vision
- Cold or pale clammy skin
- Headache

Immune effector cell-associated neurotoxicity syndrome (ICANS) symptoms to monitor for:

- Confusion or disorientation
- Hallucinations (seeing, hearing or feeling things that are not there)
- Seizures
- Problems with memory
- Problems with language (difficulty with speech or change in speech)
- Problems with judgement (change in thinking)
- Not being able to concentrate (difficulty staying awake)

Please refer to the Patient Information Leaflet (PIL) for Lunsumio for more information, which is available at:
www.medicines.org.uk.

Important Information for Healthcare Professionals

This patient has received *Lunsumio* - **which may cause Cytokine Release Syndrome and/or Immune effector cell-associated neurotoxicity syndrome (ICANS).**

- Evaluate the patient immediately for signs and symptoms of CRS and/or ICANS and treat symptoms accordingly.
- If CRS and/or ICANS is suspected, please refer to the latest product information for Lunsumio for information on CRS and ICANS management.
- **Contact the prescribing doctor immediately for further information** – they may need to modify the next infusion of Lunsumio.